Maze Therapeutics (MAZE) Cash & Equivalents (2024 - 2026)

Maze Therapeutics' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $198.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 32.48% year-over-year to $198.8 million; the TTM figure through Mar 2026 stood at $198.8 million (down 32.48% YoY), while the FY2025 annual figure was $189.2 million, down 3.84% from the prior year.
• Cash & Equivalents came in at $198.8 million for Q1 2026 at Maze Therapeutics, up from $189.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $316.8 million in Q3 2025 to a low of $30.0 million in Q1 2024.
• A 3-year average of $201.7 million and a median of $196.8 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 880.49% in 2025 and sank 32.48% in 2026, its largest moves.
• Maze Therapeutics' Cash & Equivalents stood at $196.8 million in 2024, then fell by 3.84% to $189.2 million in 2025, then gained by 5.03% to $198.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $198.8 million, $189.2 million, and $316.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison